China Retaliates Against European Union Device Manufacturers
Imposes a ban on European medical devicesGrowing China-EU Trade Conflict
The medical device industry is now the latest battleground in a growing China-EU trade conflict – with potential ripple effects across global supply chains and health procurement markets.
The AP reports that in an escalating trade dispute, China has barred European medical device companies from participating in government procurement contracts over 45 million yuan ($6.28 million). The ban, announced Sunday by China’s Finance Ministry, took effect immediately and is seen as retaliation for European Union trade restrictions on Chinese products.
Key Details:
- The ban applies only to non-Chinese-manufactured EU products.
- EU firms that produce within China are exempt.
- It mirrors a June EU policy excluding Chinese companies from public procurement over €5 million.
Broader EU-China Trade Tensions
- On Friday, China imposed anti-dumping duties on European brandy, particularly affecting French cognac.
- China is also investigating EU pork and dairy imports following EU actions targeting Chinese electric vehicles (EVs).
- The EU claims China’s procurement process discriminates against foreign firms, citing legal and administrative barriers.
China’s Response
China’s Ministry of Commerce said it had shown goodwill and willingness to negotiate but accused the EU of ignoring diplomatic overtures and erecting new protectionist barriers.
Read more here.
FDA-Approved Vivistim: A New Pathway in Stroke Recovery
Vivistim implantable vagus nerve stimulator. Source: Vivistim.com.FDA-Approved Vagus Nerve Stimulation Device Opens a New Pathway in Stroke Recovery A company behind one of the world’s most closely watched neurorehabilitation technologies is preparing for a major new...
FDA Warning Letter Cites Systemic Aseptic Manufacturing Failures
Medline Warning Letter Signals Systemic Quality Failures in Cardiovascular Device Manufacturing The FDA has issued a Warning Letter to Medline Industries (NAMIC Division) following a December 2025 inspection, identifying significant Quality System Regulation (QSR)...
FDA Approves First Gene Therapy for Genetic Hearing Loss
FDA Approves First Gene Therapy for Genetic Hearing LossRapid Review and Breakthrough Science Converge in Landmark OTOF Therapy The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first gene therapy for a form of inherited hearing loss caused by mutations in...